Biopolymeric nanoencapsulation of model drug: Its development and characterisation.
Pak J Pharm Sci
; 37(1): 85-94, 2024 Jan.
Article
en En
| MEDLINE
| ID: mdl-38741404
ABSTRACT
This research aimed to develop the phenytoin-loaded bionanosuspension by utilising the novel biopolymer from Juglans regia andreduce the long-term treatment cost of epilepsy and increase the efficiency of therapy. A novel biopolymer with remarkable inbuilt properties was isolated and used in the development of a nano capsulated dispersed system. The diverse proportions of phenytoin and biopolymer with different ratios 12, 13, 14, 15 and 18 were taken for the planning of details PJNC1-PJNC5. The bionanosuspension was assessed for dispersibility, pH, % entrapment efficiency, stability study and in vitro drug discharge. The formulation PJNC2 with 13 drug biopolymer proportion showed significant outcomes for various assessments with t50% of 16.51 h and r2 estimation of 0.9884. PJNC2 showed 92.07%±2.5 drug delivery in 36h and was stable. The bionanosuspension was found to be stable and safe for the delivery of nanosized phenytoin utilising the biopolymer having a remarkable stabiliser cum retardant property.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Fenitoína
Idioma:
En
Año:
2024
Tipo del documento:
Article